What changed for Head and Neck Cancer
A plain English summary of what recently moved in the public data Voxsanity tracks for Head and Neck Cancer. Updated from government registries. Not medical advice.
How to read these changes: every figure on this page is the difference between two snapshots of what Voxsanity had tracked on each date. Voxsanity only began taking daily snapshots in July 2026 and is still ingesting the public registries, so a rise here is mostly our own coverage expanding rather than new research appearing. Read it as our tracked coverage growing, not as a claim about real-world research changing this fast: it overstates how much actually changed.
Comparing the two most recent snapshots, 27 July 2026 and 28 July 2026.
- Trials recruiting at Australian sites 6 to 7 (+1)
- Trials recruiting worldwide 499 to 516 (+17)
- Late-stage (Phase 3) trials 74 to 77 (+3)
- Trials on record 2,666 to 2,724 (+58)
Newly subsidised on the PBS
No PBS-reviewed medicines are tracked for Head and Neck Cancer yet, so new PBS listings cannot be reported for it. This is a gap in what Voxsanity has mapped, not a statement that no medicines are subsidised — check the PBS directly.
Past updates
Tracking began in July 2026. Month on month changes will appear here once a second month of data has been recorded. Until then, the comparison above shows the most recent movement.
Recent trend
Weekly, most recent weeks (fills out to a monthly trend as history grows).
Recent trial results
The 30 most recent of 49 trials tracked for Head and Neck Cancer that have reported results to a public registry.
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
-
NCT05909904 · results posted 14 July 2026
According to the results reported on ClinicalTrials.gov, this trial enrolled 160 people in total, split evenly into four groups of 40. Each group received a different combination of three investigational medicines — tislelizumab, surzebiclimab, and alcestobart — to test them alone and in various combinations. The trial was measuring how tumours responded to these treatments in people with solid cancers, using standard imaging-based criteria to track whether tumours shrank, stayed stable, or grew. The reported data shows that the main outcome — the proportion of participants whose tumours shra...
-
NCT03780725 · results posted 13 January 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT03780725) involved two small groups of participants receiving a combination of two experimental medicines — ezabenlimab and BI 754111. Part 1 included 3 participants who received the higher dose of BI 754111 (600mg), and Part 2 included 5 participants who received a lower dose of BI 754111 (40mg), both combined with the same dose of ezabenlimab (240mg). The trial was measuring how well a specially labelled (radioactive) version of BI 754111 could be detected accumulating in tumours using medical imaging scans, taken at two...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04854499 · results posted 19 November 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04854499) enrolled a total of 193 people across six groups. It tested combinations of a drug called magrolimab (alongside other cancer medicines) in people with a type of head and neck or gastric cancer. The trial had two phases: a smaller safety "run-in" phase to check for serious early side effects, followed by a larger Phase 2 portion that looked at how well tumours responded to treatment and how long participants went without their disease getting worse. The reported data shows that in the safety run-in groups, 0% of...
-
NCT03076255 · results posted 15 October 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT03076255) enrolled 12 participants, and all 12 completed the study — none dropped out. The trial was testing a device called a Maskless Immobilization Device (MID), which is a type of support used to keep a patient's head and neck still during radiation treatment planning. The study was measuring how precisely and consistently the device could position participants, compared to the traditional method of using a custom-fitted thermoplastic mask (a firm plastic mould made to fit a patient's face). The reported data shows th...
-
NCT03552965 · results posted 30 May 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT03552965) enrolled 23 people in total — 10 in the "Margin-Based Radiotherapy Planning" group and 13 in the "Robust Radiotherapy Planning" group. The trial was comparing two different technical approaches to planning radiotherapy treatment, and it was measuring dry mouth (also called xerostomia) as its main outcome. Dry mouth is a common side effect of radiotherapy to the head and neck area. Thirteen participants completed the study (5 in the margin-based group and 8 in the robust planning group), while 10 did not complete...
-
NCT05323656 · results posted 9 May 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT05323656) enrolled 55 people in total — 27 in a group receiving setanaxib (1600 mg) combined with pembrolizumab (200 mg), and 28 in a group receiving a placebo combined with pembrolizumab. The trial was looking at how tumours responded to these treatments in terms of size changes, how long it took for the disease to progress, and changes in certain cells found in tumour tissue. Only 1 participant in each group completed the study, with the large majority not completing it. The reported data shows that for the primary meas...
-
NCT03452137 · results posted 9 October 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT03452137) enrolled 406 people in total — 203 in a placebo group and 203 in a group receiving a medicine called atezolizumab. All participants had been treated for a type of head and neck cancer (squamous cell carcinoma of the head and neck). The trial was mainly measuring "event-free survival" — that is, how long people went without their cancer coming back, spreading, or progressing, or without dying. This was tracked from the point each person was randomly assigned to their group. The reported data shows that the median...
-
NCT04905134 · results posted 19 September 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 53 participants who each underwent two examinations of the upper airway and throat — one using a standard camera scope (called a nasopharyngoscope, a thin flexible tube passed through the nose to look at the throat) and one using a new prototype version of the same type of device. Three participants did not complete the first examination, so 50 participants went on to complete both exams. The trial was measuring how easy the new prototype scope was for providers to use, how good the image quality was from each device,...
-
NCT02777385 · results posted 1 August 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 80 people with cancer who were split into two groups. Forty-one participants received pembrolizumab (an immunotherapy drug) at the same time as their standard treatment of cisplatin (a chemotherapy) and radiation — this is called the "concurrent" group. The other 39 participants received the same standard treatment first, with pembrolizumab added afterwards in a "sequential" approach. The trial was primarily measuring how many participants went a certain length of time without their disease getting worse (called progr...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03719690 · results posted 21 June 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT03719690) involved two groups of participants with head and neck cancer. Fifty-nine people received the study drug tipifarnib (the treatment group, called AIM-HN), and 237 people were enrolled in a separate observational group (SEQ-HN) who did not receive tipifarnib and were followed for comparison purposes only. The trial was primarily measuring what proportion of participants in the tipifarnib group showed a measurable shrinkage in their tumours, and it focused particularly on patients whose tumours had a high level of a...
-
NCT04217057 · results posted 28 February 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 11 participants, and all 11 completed the study with no one dropping out. The trial was testing a specialised imaging scan called 64Cu-DOTA-ECL1i-PET/CT — a type of body scan that uses a small amount of radioactive material designed to highlight certain immune cells (known as CCR2-expressing cells) in the body. The study was measuring whether the scan produced images good enough to be useful for diagnosis, and whether it could detect those immune cells at sites of known disease. The reported data shows that when rese...
-
NCT04634825 · results posted 20 December 2023
According to the results reported on ClinicalTrials.gov, this trial looked at two different drug combinations in people with cancer. One group of 48 participants received a combination of two drugs called enoblituzumab and retifanlimab, while a second group of 14 participants received enoblituzumab combined with a different drug called tebotelimab. The trial measured how many people's tumours shrank or disappeared (called the overall response rate), how many people experienced unwanted side effects (adverse events), and how long it took for the disease to get worse or for people to stay stable...
-
NCT04154943 · results posted 8 February 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT04154943) enrolled 79 participants, all of whom received cemiplimab (350 mg every three weeks) before surgery — a treatment approach sometimes called "neoadjuvant" therapy, meaning it is given ahead of an operation. The trial was primarily measuring how many participants showed a "pathologic complete response" (pCR), which means that when surgeons and pathologists examined the tissue removed during surgery, no living cancer cells could be found. The reported data shows that out of 79 participants, 40 had a pathologic comp...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04428333 · results posted 25 May 2022
According to the results reported on ClinicalTrials.gov, this trial enrolled 117 people in total — 57 in one group and 60 in the other. Participants had cancer and were randomly assigned to receive one of two treatment combinations: one group received feladilimab together with pembrolizumab and a standard chemotherapy regimen (5-FU-platinum), while the other group received a placebo together with the same pembrolizumab and chemotherapy combination. The trial was primarily measuring how long participants lived overall (called "overall survival"), and how long they lived without their cancer get...
Read the full trial page · View reported results on ClinicalTrials.gov ↗
-
NCT04128696 · results posted 24 May 2022
According to the results reported on ClinicalTrials.gov, this trial enrolled 315 people in total — 158 in the group receiving both feladilimab and pembrolizumab, and 157 in the group receiving a placebo alongside pembrolizumab. The trial was measuring two main things: how long participants lived overall (called "overall survival"), and how long they lived without their disease getting worse (called "progression-free survival"). These measurements were looked at in two subgroups — participants whose tumours showed a certain protein marker (PD-L1) at a moderate level or higher, and those whose t...
-
NCT02741570 · results posted 3 May 2022
According to the results reported on ClinicalTrials.gov, this trial (NCT02741570) enrolled 472 people in the nivolumab plus ipilimumab group and 475 people in the EXTREME regimen group (a standard chemotherapy-based combination), for a total of 947 participants. The trial was measuring overall survival — that is, how long people lived after being randomly assigned to one of the two treatments — as its main goal. It looked at this both across all participants and within a subgroup whose tumours showed higher levels of a particular protein marker called PD-L1 (measured by a "combined positive sc...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02682992 · results posted 13 April 2022
According to the results reported on ClinicalTrials.gov, this trial enrolled 47 participants, all of whom completed the study with no drop-outs. All participants received low level laser therapy (a type of light-based treatment applied to the mouth) while undergoing radiotherapy for head and neck cancer. The trial was measuring how often participants developed severe mouth sores — known as oral mucositis — during their radiation treatment, specifically in those who received a cumulative radiation dose of at least 5,000 cGy (a unit used to measure radiation). The reported data shows that 23% o...
-
NCT03682367 · results posted 9 July 2021
According to the results reported on ClinicalTrials.gov, this trial (NCT03682367) enrolled a total of 8 participants, split evenly into two groups of 4 — a control group and an intervention group. The trial was measuring differences in pain-related outcomes between the two groups, specifically looking at the amount of opioid pain medication used (measured in "morphine equivalent units," a standard way of comparing different pain medicines), self-reported pain scores on a 1-to-10 scale, and the occurrence of complications after surgery or related to pain medication use. The reported data shows...
-
NCT02130427 · results posted 1 July 2021
According to the results reported on ClinicalTrials.gov, this trial (NCT02130427) enrolled 74 participants in a single group called the "Imaging" group. The trial was designed to measure how a tumour's size, movement, and the surrounding body area changed during a type of radiation treatment called photon beam radiotherapy. To track these changes, the study used specialised medical scans — either 4D or 3D CT scans (detailed X-ray images that can capture movement) and/or a series of MRI scans (images that use magnetic fields rather than X-rays). The reported data shows that 44 of the 74 partic...
-
NCT01403064 · results posted 11 May 2021
According to the results reported on ClinicalTrials.gov, this trial enrolled 76 people in total across four groups. Participants were receiving radiation therapy for head and neck cancer and were being treated with either a placebo (an inactive substance) or one of two doses of an experimental drug called ALD518 — either 160 mg or 320 mg. The trial was primarily measuring how often participants experienced unwanted health events (called adverse events), serious adverse events, and notable changes in laboratory test results. It also measured how often participants developed a painful mouth cond...
Read the full trial page · View reported results on ClinicalTrials.gov ↗
-
NCT01716195 · results posted 26 February 2021
According to the results reported on ClinicalTrials.gov, this trial enrolled 18 people, all of whom received a treatment approach called "response adapted chemoradiation" — meaning the radiation and chemotherapy plan was adjusted based on how each person's body was responding during treatment. Seventeen of the 18 participants completed the study, and one did not. The trial was measuring how many participants went two years without their disease getting worse (called "progression-free survival"), how many participants were still alive over the course of the study (called "overall survival"), an...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02952586 · results posted 24 February 2021
According to the results reported on ClinicalTrials.gov, this trial (NCT02952586) enrolled 697 people with head and neck cancer — 350 in the group receiving avelumab (an immunotherapy drug) alongside standard chemotherapy and radiation treatment, and 347 in the group receiving a placebo alongside the same standard treatment. The trial was designed to measure how long participants went without their cancer getting worse (called progression-free survival), as well as a number of other outcomes including how long participants lived overall, how their tumours responded to treatment, and whether ca...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02633540 · results posted 17 February 2021
According to the results reported on ClinicalTrials.gov, this trial (NCT02633540) enrolled 2 participants, both of whom completed the study. The trial involved a single group of people who received a type of targeted radiation treatment (called IMRT) for early-stage larynx (voice box) cancer. The study was designed to look at three things: how participants rated the impact of their voice on daily life, how satisfied they were with their swallowing, and how a clinician assessed their swallowing function — all measured at various points up to 24 months after finishing treatment. The reported da...
-
NCT03821064 · results posted 1 February 2021
According to the results reported on ClinicalTrials.gov, this trial (NCT03821064) tested a patient navigation programme called NDURE, which was designed to help people with head and neck cancer start their post-surgery radiation treatment on time. Eleven people enrolled in the study and ten completed it, with one person not finishing. The main thing the trial was measuring was how many participants had a delay in starting radiation — meaning it took more than six weeks (42 days) after surgery before radiation began. The reported data shows that out of the ten participants, 4 were recorded as...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02163057 · results posted 23 December 2020
According to the results reported on ClinicalTrials.gov, this trial enrolled 22 people in total — 6 in a surgery group (Cohort 1) and 16 in a chemoradiation group (Cohort 2). The trial was measuring the body's responses after receiving an investigational HPV-related treatment, specifically looking at two things: unwanted health events (called adverse events) that occurred during the study, and various markers in the blood that researchers used to track how the immune system — the body's defence system — was responding over time. The reported data shows that when it came to unwanted health eve...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03255980 · results posted 16 December 2020
According to the results reported on ClinicalTrials.gov, this trial (NCT03255980) looked at a product called Xonrid, used alongside standard-of-care treatment, in people undergoing radiotherapy for either breast cancer or head and neck cancer. Each of the four groups started with 20 participants — giving 80 people in total across the trial. The trial was mainly measuring how many people avoided a moderate level of skin reaction (called Grade 2 radiodermatitis, a type of skin irritation caused by radiation) by the fifth week of treatment. A number of participants did not complete the study: in...
-
NCT03057613 · results posted 19 October 2020
According to the results reported on ClinicalTrials.gov, this trial (NCT03057613) involved 18 participants who all completed the study. The trial was looking at a combination of a medicine called pembrolizumab given alongside post-operative radiotherapy (radiation treatment after surgery). The study had two main things it was measuring: first, whether certain serious side effects — called dose-limiting toxicities, meaning unwanted reactions severe enough to limit the treatment — occurred during or shortly after treatment; and second, how many participants went a period of time without their di...
-
NCT02608879 · results posted 28 August 2020
According to the results reported on ClinicalTrials.gov, this trial (NCT02608879) enrolled 19 people in total. Ten participants were placed in the OMDP (treatment) group, six in a control group, and three were not randomised into either group. The trial was measuring the severity of oral mucositis — a painful inflammation and ulceration of the mouth that can occur during cancer treatment — using two standard rating scales (the WHO scale and the NCI scale). It also looked at participants' pain levels and changes in the mix of bacteria found in the mouth. The reported data shows the following f...
-
NCT01976741 · results posted 28 April 2020
According to the results reported on ClinicalTrials.gov, this trial (NCT01976741) tested a drug called rogaratinib in people with advanced cancer, across several groups. A total of 168 participants were enrolled across all groups — including a dose-escalation phase (where six different twice-daily doses ranging from 50 mg to 800 mg were tested in small groups of 3–4 people each) and a dose-expansion phase (where larger groups of participants with specific cancer types, including bladder cancer, head and neck cancer, and a type of lung cancer, received the drug). The trial was primarily measuri...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT01111058 · results posted 7 April 2020
According to the results reported on ClinicalTrials.gov, this trial involved 52 people in total — 28 who received a medicine called everolimus (also known as RAD001) and 24 who received a placebo (a dummy treatment with no active ingredient). All 52 participants completed the study, with no drop-outs recorded. The trial was measuring how many people remained free from their disease getting worse over a two-year period, as well as tracking where in the body any worsening occurred, whether a second new tumour developed, and how many people experienced any unwanted side effects. The reported dat...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
See all 49 reported results for Head and Neck Cancer
These are the results as reported to the registry, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
What is coming
AI generated pipeline summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to NIH funding data, head and neck cancer currently attracts a very large amount of public research investment from the United States government. This level of funding has remained broadly steady over recent years, which suggests that the scientific community sees head and neck cancer as an ongoing and serious research priority. For patients, this sustained commitment generally means tha...
See the full Head and Neck Cancer page
Not medical advice. Voxsanity republishes public government health data in plain English. These figures describe research and registry activity, not the suitability of any treatment for any person. Trial status can change; always verify current status directly with the trial site and confirm Australian availability with your doctor.